The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens

@article{Schweizer2007TheAR,
  title={The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens},
  author={Liang Schweizer and Cheryl A Rizzo and Thomas E Spires and J. Suso Platero and Qiuyan Wu and Tai-an Lin and Marco M. Gottardis and R. Attar},
  journal={BMC Cell Biology},
  year={2007},
  volume={9},
  pages={4 - 4}
}
A crucial event in Prostate Cancer progression is the conversion from a hormone-sensitive to a hormone-refractory disease state. Correlating with this transition, androgen receptor (AR) amplification and mutations are often observed in patients failing hormonal ablation therapies. β-Catenin, an essential component of the canonical Wnt signaling pathway, was shown to be a coactivator of the AR signaling in the presence of androgens. However, it is not yet clear what effect the increased levels… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
48 Extracted Citations
58 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 48 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 58 references

Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line

  • CG Tepper
  • Cancer Res
  • 2002
Highly Influential
8 Excerpts

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

  • J Veldscholte
  • Biochem Biophys Res Commun
  • 1990
Highly Influential
8 Excerpts

Time course of serum testosterone and luteinizing hormone levels after cessation of long - term luteinizing hormonereleasing hormone agonist treatment in patients with

  • MV Cronauer
  • prostate cancer Prostate
  • 2006

Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer

  • H Kaku
  • Prostate
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…